Kioxia targets 2027 US listing; filings show no $10B raise

Kioxia Holdings is preparing an American Depositary Share program to give U.S. investors access to its stock. Management said in June that it hopes to list ADSs around April, May or June 2027, and depositaries have filed Form F-6 registration statements with the U.S. Securities and Exchange Commission.

Those filings do not support a claim that Kioxia is raising more than $10 billion of equity. Form F-6 registers depositary receipts, which allow an underlying foreign share to trade in the United States. In the July 10 filing, the box asking whether a separate registration statement had been filed to register the deposited shares is unchecked.

The program can broaden the institutions able or willing to own Kioxia's equity without adding cash to its balance sheet or diluting existing shareholders. A primary capital raise would require a separate offering that identifies newly issued securities, the offering price, underwriters, proceeds and use of funds.

What the depositary filings register

An April filing covered up to 50 million ADSs, each representing one-tenth of a Kioxia common share. Its $2.5 million aggregate figure was used to calculate the SEC registration fee; it does not represent proceeds for Kioxia. The July Deutsche Bank filing likewise concerns the ADS program without disclosing a Kioxia share sale.

Kioxia's stock valuation has risen sharply with the AI-memory cycle, and CFO Yoshihiko Kawamura said the U.S. listing is intended to expand the investor base. A U.S. security can ease mandate, settlement or market-access restrictions for institutions that do not buy Tokyo-listed shares directly. It can also give Kioxia a way to raise U.S. capital later.

A depositary listing can improve liquidity and analyst coverage with no immediate dilution. A primary offering would dilute existing owners in exchange for balance-sheet cash. A secondary sale by an existing holder would change ownership without funding Kioxia at all. An ADS structure can support each transaction, with different consequences for shareholders.

Evidence of a primary raise would appear in a separate issuer securities registration or offering prospectus specifying newly issued shares and cash proceeds. The registered ADS count does not supply that evidence. For now, the potential benefit is a wider pool of buyers following the stock's sharp rise; assuming $10 billion of new cash and the associated dilution goes beyond the filings.

Sources

• Kioxia Form F-6 filed July 10, 2026: https://www.sec.gov/Archives/edgar/data/1471515/000110465926082525/tm2620156d1_f6ef.htm
• Kioxia/Citibank Form F-6 filed April 24, 2026: https://www.sec.gov/Archives/edgar/data/1472033/000119380526000504/e665408_f6ef-kioxia.htm
• SEC filing index for the April F-6: https://www.sec.gov/Archives/edgar/data/2053383/0001193805-26-000504-index.htm
• Reuters, Kioxia's 2027 U.S.-listing timetable, republished by Investing.com: https://www.investing.com/news/stock-market-news/kioxia-shares-slump-12-as-airelated-stocks-fall-4762012